Conferences

Catalog

Abstracts

Calendar

2026 Oklahoma Thoracic Oncology Conference

Accreditation: 5.25 AMA PRA Category 1 Credit™ | 5.25 Nursing Contact Hours | 5.25 ACPE Pharmacy | 5.25 ABIM MOC II

Venue: Okana Resort & Indoor Waterpark , 639 First Americans Boulevard, Oklahoma City, OK, United States

Start Date: March 7, 2026

Overview

Trusted by Thousands of Attendees
Across Our Events

53+

Email if you have questions

Our Speakers

Planning Committee

Abdul Rafeh Naqash, MD

Conference Chair

Stephenson Cancer Center , University of Oklahoma

Raid Aljumaily, MD

Conference Chair

University of Oklahoma

Clay T Reed, MD

Conference Chair

Integris Cancer Institute

Faculty

Ashtin Taylor, PharmD, PharmD

Session Chair

Stephenson Cancer Center , University of Oklahoma

Raid Aljumaily, MD

Session Chair

University of Oklahoma

Abdul Rafeh Naqash, MD

Session Chair

Stephenson Cancer Center , University of Oklahoma

Clay T Reed, MD

Session Chair

Integris Cancer Institute

Jonathan Dowell, MD

Session Chair

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center

Tyler Gunter, MD

Session Chair

Nirmal Choradia, MD

Session Chair

University of Oklahoma

L. Kyle Brett, MD

Session Chair

Utica Park Clinic

Siddhartha Devarakonda, MD

Session Chair

Swedish/Providence

Fawad Chaudry MD.,FCCP, MD

Session Chair

University of Oklahoma

Muhammad Furqan, MD

Session Chair

Stephenson Cancer Center , University of Oklahoma

Fawzi F Abu Rous, MD

Faculty

Henry Ford Health

Maida Hafiz, MD

Faculty

OU Health

Bilal Ahmad, MD, MD

Faculty

Biagio Ricciuti, MD

Faculty

Dana-Farber Cancer Institute

Steven H Lin, MD, PhD

Faculty

The University of Texas MD Anderson Cancer Center

Firas Muhammad Jafri, MD

Faculty

Oklahoma University Stephenson Cancer Center at Hillcrest

Irim Yasin, MD, MD

Faculty

Integris Cancer Institute

Jordan Malie Morton, MD

Faculty

Chul Kim, MD

Faculty

Mohamed Hassan, MD

Faculty

OUHSC

Amy Eberle, ARNP

Faculty

OU Health

Debra Richardson, MD, Other

Faculty

Debra Lynn Richardson, M.D., F.A.C.O.G., F.A.C.S

Nirmal Vimalchand Choradia, MD

Faculty

Stephenson Cancer Center , University of Oklahoma

Yasir Elamin, MD

Faculty

MD Anderson Cancer Center

Sarah K Hayward, PharmD

Faculty

OU Health Stephenson Cancer Center

Falah Fayaz, MD

Faculty

Stephenson Cancer Center , University of Oklahoma

Mark Doescher, MD, MSPH

Faculty

Paul El Tomb, MD, MD

Faculty

Joshua Glover, MD

Faculty

University of Oklahoma

Hassan Kaleem, MD

Faculty

Ajay Sheshadri, MD, MSCI

Faculty

Raymond Osarogiagbon, MD

Faculty

Nathaniel Moulton, MD

Faculty

Integris Cancer Institute

Nagla Abdel Karim, MD

Faculty

The George Washington University

Nishant Rajendra Tiwari, MD

Faculty

Stephenson Cancer Center , University of Oklahoma

Ranjit B Jasaraj, MD, MD

Faculty

Oklahoma University Health Science Center

Matthew Reinersman, MD

Faculty

Stephenson Cancer Center , University of Oklahoma

Houssein Youness, MD, MD

Faculty

The University of Oklahoma Health Sciences Center

Aadel Chaudhuri, MD

Faculty

Washington University in St. Louis

Our Agenda

Saturday, March 7th, 2026

All timings are in Central Time (CDT, GMT-05:00) time.

07:00 AM - 08:00 AMRegistration, Breakfast, & Exhibits (Sunrise Ballroom 2)

08:00 AM - 08:10 AMWelcome ( Sunrise Ballroom 1)

08:10 AM - 08:50 AMSession 1: Peri-operative IO is the New Default-Where paradigms are shifting ( Sunrise Ballroom 1)

Session Chair: Raid Aljumaily, MD

08:10 AM - 08:25 AM

Updates in perioperative treatment and Role of pathological response in early stage NSCLC – Chul Kim, MD

08:25 AM - 08:37 AM

Case-based Discussion – Amy Eberle, ARNP; Chul Kim, MD; Mohamed Hassan, MD; Matthew Reinersman, MD; Ranjit B Jasaraj, MD, MD; Raid Aljumaily, MD

08:38 AM - 08:50 AM

Case-based Discussion – Matthew Reinersman, MD; Chul Kim, MD; Mohamed Hassan, MD; Amy Eberle, ARNP; Nishant Rajendra Tiwari, MD; Raid Aljumaily, MD

08:50 AM - 09:15 AMSession 2: EGFR: Single-Agent vs Combo “Amivantamab + Lazertinib vs Osimertinib: Combination Strategy vs Monotherapy for 1L EGFR exon 19/21 Mutations ( Sunrise Ballroom 1)

Session Chair: Jonathan Dowell, MD

08:50 AM - 09:05 AM

Amivantamab + Lazertinib vs Osimertinib: Combination Strategy vs Monotherapy for 1L EGFR exon 19/21 Mutations – Yasir Elamin, MD

09:05 AM - 09:15 AM

Panel Discussion – Paul El Tomb, MD, MD; Irim Yasin, MD, MD; Hassan Kaleem, MD; Jordan Malie Morton, MD; Yasir Elamin, MD; Jonathan Dowell, MD

09:15 AM - 09:30 AMSession 3: KeyNote ( Sunrise Ballroom 1)

09:15 AM - 09:30 AM

KRAS in NSCLC: Drive to targeted therapies-Current Insights – Nagla Abdel Karim, MD

09:30 AM - 10:00 AMSession 4: Screening & Risk: Beyond Pack-Years ( Sunrise Ballroom 1)

Session Chair: Nirmal Choradia, MD

09:30 AM - 09:40 AM

Lung Cancer Screening 3.0: AI, Risk Models, and Incidentalomas – Who Actually Belongs in the Scanner? – Nirmal Vimalchand Choradia, MD

09:40 AM - 09:50 AM

Risk-adapted screening, AI/radiomics, overdiagnosis, and incidental findings – Raymond Osarogiagbon, MD

09:50 AM - 10:00 AM

Panel Discussion – Mark Doescher, MD, MSPH; Nathaniel Moulton, MD; Raymond Osarogiagbon, MD; Houssein Youness, MD, MD; Nirmal Choradia, MD; Fawad Chaudry MD.,FCCP, MD

10:00 AM - 10:35 AMSession 5: Formal Debate – “Looking into the Future: ctDNA-MRD and Pathologic Response – Driving Escalation and De-escalation of Adjuvant Therapy in Early-Stage NSCLC” ( Sunrise Ballroom 1)

Session Chair: L. Kyle Brett, MD

10:00 AM - 10:10 AM

Pro Position (MRD-positive = escalate (IO/TKI/ADC); MRD-negative = safely de-escalate) – Aadel Chaudhuri, MD

10:10 AM - 10:20 AM

Con Position (Assay variability, lead-time bias, lack of de-escalation data, risk of undertreating curable disease) – Amin Nassar, MD

10:20 AM - 10:25 AM

Audience Q&A with live polling

10:25 AM - 10:35 AM

Panel Discussion – Aadel Chaudhuri, MD; Amin Nassar, MD; L. Kyle Brett, MD

10:35 AM - 10:45 AMBreak & Exhibits (Sunrise Ballroom 2)

10:45 AM - 11:15 AMSession 6: ADC Tsunami in NSCLC From T-DXd to Dato-DXd: Are ADCs the New TKIs? ( Sunrise Ballroom 1)

Session Chair: Ashtin Taylor, PharmD, PharmD

10:45 AM - 10:55 AM

HER2/HER3 and TROP2 ADCs in metastatic NSCLC efficacy vs ILD and other toxicities. – Ashtin Taylor, PharmD, PharmD

10:55 AM - 11:05 AM

Can Antibody–Drug Conjugates Replace Docetaxel in Non-Oncogene NSCLC in the Second Line? – Fawzi F Abu Rous, MD

11:05 AM - 11:15 AM

Case-based Discussion – Ajay Sheshadri, MD, MSCI; Maida Hafiz, MD; Fawzi F Abu Rous, MD; Joshua Glover, MD; Ashtin Taylor, PharmD, PharmD

11:15 AM - 11:50 AMSession 7: Lung Toxicity ( Sunrise Ballroom 1)

Session Chair: Fawad Chaudry MD.,FCCP, MD

11:15 AM - 11:25 AM

ADC and ICI lung toxicity : Are we getting any better in diagnosing or managing – Maida Hafiz, MD

11:25 AM - 11:35 AM

Pneumonitis on Novel ADCs from Phase 1 trials – Falah Fayaz, MD

11:35 AM - 11:50 AM

Discussion – Sarah K Hayward, PharmD; Maida Hafiz, MD; Debra Richardson, MD, Other; Ajay Sheshadri, MD, MSCI; Fawad Chaudry MD.,FCCP, MD

11:50 AM - 12:20 PMSession 8: SCLC: Changing Horizons The Last Two Years vs the Last 25 Years ( Sunrise Ballroom 1)

Session Chair: Muhammad Furqan, MD

11:50 AM - 12:00 PM

Practice-changing data for the frontline setting and maintenance strategies in LS-SCLC & ES-SCLC; redefining SCLC care – Nagla Abdel Karim, MD

12:00 PM - 12:10 PM

Tarlatamab and Tarlatamab-Based Combinations in SCLC – Abdul Rafeh Naqash, MD

12:10 PM - 12:20 PM

Panel Discussion – Bilal Ahmad, MD, MD; Nagla Abdel Karim, MD; Muhammad Furqan, MD; Abdul Rafeh Naqash, MD

12:20 PM - 01:20 PMLunch & Exhibits(Sunrise Ballroom 2) ; Product Theater sponsored by Amgen (Non CME Accredited) : The First and Only DLL3-Targeting Bispecific T-cell Engager (BiTE®) Therapy for 2L ES-SCLC - Sarah Karpen, PA ( Redbud Room)

This activity is supported with a Independent Medical Education grant from: Gilead

About 2026 Oklahoma Thoracic Oncology Conference

Overview

Faculty and committee

Our Speakers

Planning Committee

Faculty

Conference program and agenda

Our Agenda

Venue and map

Accreditations and continuing education

Registration and pricing

Exhibitors and sponsorship

Our Speakers

Planning Committee

Faculty

Our Agenda